NuCana plc
Business
NuCana plc is a clinical-stage biopharmaceutical company developing ProTide-transformed chemotherapy agents to treat cancer more effectively and safely. The company's pipeline includes NUC-7738, a phosphoramidate prodrug disrupting RNA polyadenylation in cancer cells, and NUC-3373, a targeted thymidylate synthase inhibitor derived from 5-fluorouracil, both in Phase 1/2 or Phase 1b/2 clinical trials. NuCana operates globally with development and commercialization activities in the United States and Europe.
Summary from 20-F filed 2026-03-19
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-29.35M |
| Total assets | $29.83M |
| Total liabilities | $5.51M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NuCana plc's CIK number?
NuCana plc's SEC CIK number is 0001709626 (1709626). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NuCana plc's SEC filings?
All of NuCana plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.